- Home
- TNGX vs GILT Comparison
TNGX vs GILT Comparison
Compare TNGX & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GILT
- Stock Information
- Founded
- TNGX 2014
- GILT 1987
- Country
- TNGX United States
- GILT Israel
- Employees
- TNGX N/A
- GILT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GILT Radio And Television Broadcasting And Communications Equipment
- Sector
- TNGX Health Care
- GILT Technology
- Exchange
- TNGX Nasdaq
- GILT Nasdaq
- Market Cap
- TNGX 351.2M
- GILT 381.2M
- IPO Year
- TNGX N/A
- GILT 1993
- Fundamental
- Price
- TNGX $6.01
- GILT $7.38
- Analyst Decision
- TNGX Strong Buy
- GILT Strong Buy
- Analyst Count
- TNGX 6
- GILT 2
- Target Price
- TNGX $12.20
- GILT $8.50
- AVG Volume (30 Days)
- TNGX 2.7M
- GILT 458.0K
- Earning Date
- TNGX 08-06-2025
- GILT 08-06-2025
- Dividend Yield
- TNGX N/A
- GILT N/A
- EPS Growth
- TNGX N/A
- GILT N/A
- EPS
- TNGX N/A
- GILT 0.24
- Revenue
- TNGX $40,990,000.00
- GILT $321,407,000.00
- Revenue This Year
- TNGX N/A
- GILT $42.88
- Revenue Next Year
- TNGX N/A
- GILT $13.26
- P/E Ratio
- TNGX N/A
- GILT $31.38
- Revenue Growth
- TNGX 10.09
- GILT 13.49
- 52 Week Low
- TNGX $1.03
- GILT $4.04
- 52 Week High
- TNGX $12.02
- GILT $8.07
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- GILT 63.94
- Support Level
- TNGX $5.34
- GILT $7.01
- Resistance Level
- TNGX $6.40
- GILT $8.07
- Average True Range (ATR)
- TNGX 0.50
- GILT 0.27
- MACD
- TNGX -0.02
- GILT 0.05
- Stochastic Oscillator
- TNGX 84.08
- GILT 58.61
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.